Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Awareness Campaign Launched As Measles Rises, UK
Measles vaccination rates are still far lower than levels needed to protect the population. This is despite the finding of a new Department of Health survey that over 90 per cent of parents are aware it is the best way to protect their child.

Blood Tests And Better Communication Skills Could Cut Over-prescribing Of Antibiotics
Improving communications skills and the use of a simple blood test could help cut the growing
News of the day
FDA Approves Samsca For The Treatment Of Hyponatremia
The FDA (Food and Drug Administration) has approved Samsca (tolvaptan), in tablet form, for the treatment of hyponatremia. Hyponatremia is when levels of sodium in the blood are abnormally low - it is associated with dehydration.
Oncology

PharmaCom BioVet To File With FDA In Order To Perform Clinical Trials - Cancer Treatment For Canines

PharmaCom BioVet, Inc. (PINKSHEETS: PHMB) is pleased to announce that it is preparing a Form 21 CFR 511.1(b) for submission to the Federal Drug Administration (FDA). This initial form is one of several required if the Corporation decides to potentially run clinical trials on a histone deacetylase inhibitor for canines, which the Corporation is planning to develop. The histone deacetylase inhibitor is potentially for dogs suffering from an acute type of cancer, canine hemangiosarcoma. "We are pleased to announce this filing with the FDA, because it is another positive step towards implementing our business plan and could possibly lead to future testing of cancer treatment medications for canines," stated Gary Berthold, President of PharmaCom BioVet, Inc. PharmaCom BioVet, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009